Editors choice: A Systematic Review of Decipher Genomic Classifier Risk Scores for Prostate Cancer in African-Americans

Author(s): Mahnoosh Rahimi and Sheldon Greenfield*

Background: Prostate Cancer (PCa) is a non-cutaneous malignancy in men, and Decipher being a genomic test, has gained increasing attention in estimating the risk of developing a recurrence or metastatic PCa disease in patients. Therefore, this study is focused on evaluating the association of Decipher score risk with recurrence of prostate cancer patients based on their medical, genetic predictors, and demographics (e.g., races) by conducting a systematic review. Moreover, the study has also assessed whether Decipher score risk can be a good predictor for prostate patients’ metastasis and prostate cancer-specific mortality in men and clinical decision-making regarding patient treatment recommendations.

Methods: The research study has reviewed 74 research articles, and the systematic review results have been presented in the form of themes. The studies’ review indicated that Decipher acts as a genomic metastasis signature to predict metastatic disease among patients and make better decisions about treating the disease. Moreover, this genomic test can also be used in conjunction with Magnetic Resonance Imaging (MRI) for identifying the lesions that may carry the biological potential for early metastases. Furthermore, this review also identified that treatment options for PCa might range from Adjuvant Radiation Treatment (ART) and Salvage Radiation Therapy (SRT) to Radical Prostatectomy (RP); however, the selection of treatment methodology depends upon the GC score and risk stratification.

Results: The results further suggested that the occurrence of PCa is two folds greater among African-Americans (AA) men as compared to non-AA men. Thus, the increasing incidence of PCa among AA and discrimination within AA’s health and socio-economic conditions plays a significant role in treating AA. In this scenario, the Decipher test score plays an essential role in making treatment decisions.

Conclusion: To conclude, further trials are still required for validating the Decipher biomarkers, and scientists should enhance the decipher test ability to be run on a patient’s blood samples instead of tumor tissue, which will help patients use decipher as a screening test at the asymptomatic level.

Download and Read: https://bit.ly/3FD4yI7

New Issue | MicroRNA; Volume 9 Issue 1

 

 

MicroRNA publishes letters, full-length/ mini reviews, research articles, drug clinical trial studies and thematic issues on all aspects of microRNA (miRNA) research. The scope of the journal covers all experimental miRNA research and applied research in health and disease, including therapeutic, biomarkers, and diagnostic applications of MiRNA.

 

Articles from the journal: MicroRNA; Volume 9 Issue 1

• The Role of microRNAs Identified in the Amniotic Fluid
• Updates on the Current Technologies for microRNA Profiling open access plus
• Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma open access plus
• Neglected Tropical Diseases: The Potential Application of microRNAs for Monitoring NTDs in the Real World open access plus
• The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients
• Overexpression of microRNA-21 in the Serum of Breast Cancer Patients
• The KLF6 Super Enhancer Modulates Cell Proliferation via MiR-1301 in Human Hepatoma Cells
• Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly via Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling open access plus

For details on the articles, please visit this link: http://www.eurekaselect.com/node/99280/microrna-/issue/9/2680/1/9490

Testimonial by Dr. Yi Da!

 

 

READ WHAT OUR AUTHORS HAVE TO SAY ABOUT PUBLISHING IN OUR JOURNAL

 

Journal Name: Current Drug Metabolism

Contributed Article: Serial Quantification of Urinary Protein Biomarkers to Predict Drug-induced Acute Kidney Injury

Become an Editorial Board Member (EBM) | Current Nutraceuticals

 

“Current Nutraceuticals” publishes original research articles, mini- and full-length reviews, feature articles, technical notes and thematic issues covering all aspects of nutraceuticals, from the isolation and comprehensive characterization of secondary metabolites and their synthesis to the biological activity of nutritional constituents and antioxidants, clinical, population, ethnological and agricultural studies. The journal also explicitly welcomes interdisciplinary contributions considering wider social, cultural, ethical and applied aspects of nutraceuticals and nutrition in modern society.

• Isolation and comprehensive chemical and physical characterization of active ingredients
• Secondary metabolites from plants and (micro-)organisms
• Antioxidants
• Chemoprevention
• Biomarkers of nutrition and health
• Chemistry of nutraceuticals, including synthesis
• Nutrition and ageing
• Nutrition and lifestyle
• Nutraceuticals and drug development
• Nutraceuticals in agriculture
• Healthy diets
• Nutraceuticals in Society: Wider cultural, social, ethical, ecological and economic implications

The Journal “Current Nutraceuticals“ is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at: hermain@benthamscience.net and CC: faizan@benthamscience.net

 

Open Access Articles – Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model

Journal Name: Current Pharmaceutical Biotechnology

Author(s): Moritz Haaf, Gregor Leicht, Stjepan Curic, Christoph Mulert*.

 

 

 

Graphical Abstract:

 

 

Abstract:

Background: The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. NMDAR hypofunction can explain many schizophrenia symptoms directly due to excitatory-to-inhibitory (E/I) imbalance, but also dopaminergic dysfunction itself. However, so far no new drug targeting the NMDAR has been successfully approved. In the search for possible biomarkers it is interesting that ketamine-induced psychopathological changes in healthy participants were accompanied by altered electro-(EEG), magnetoencephalographic (MEG) and functional magnetic resonance imaging (fMRI) signals.

Methods: We systematically searched PubMed/Medline and Web of Knowledge databases (January 2006 to July 2017) to identify EEG/MEG and fMRI studies of the ketamine model of schizophrenia with human subjects. The search strategy identified 209 citations of which 46 articles met specified eligibility criteria.

Results: In EEG/MEG studies, ketamine induced changes of event-related potentials, such as the P300 potential and the mismatch negativity, similar to alterations observed in schizophrenia patients. In fMRI studies, alterations of activation were observed in different brain regions, most prominently within the anterior cingulate cortex and limbic structures as well as task-relevant brain regions. These alterations were accompanied by changes in functional connectivity, indicating a balance shift of the underlying brain networks. Pharmacological treatments did alter ketamine-induced changes in EEG/MEG and fMRI studies to different extents.

Conclusion: This review highlights the potential applicability of the ketamine model for schizophrenia drug development by offering the possibility to assess the effect of pharmacological agents on schizophrenia- like symptoms and to find relevant neurophysiological and neuroimaging biomarkers.

 

 

For more details, please visit: http://www.eurekaselect.com/163122

New Issue :: MicroRNA (Volume: 7, Issue: 3)

 

MicroRNA publishes letters, full-length research, review articles, drug clinical trial studies and thematic issues on all aspects of microRNA (miRNA) research. The scope of the journal covers all experimental miRNA research and applied research in health and disease, including therapeutic, biomarkers, and diagnostic applications of MiRNA.

 

 

Articles from the journal MicroRNA Volume 7, Issue 3:

• Functional Role of microRNA-23b-3p in Cancer Biology
• Role of MicroRNA in the Diagnosis and Therapy of Hepatic Metastases from Colorectal Cancer
• Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by microRNAs
• Investigating the Isolation and Amplification of microRNAs for Forensic Body Fluid Identification
• The Influence of Pre-analytical Factors on the Analysis of Circulating MicroRNA
• Human MicroRNAs Expression Profiles in Influenza B Virus-Infected Cells based on Illumina MiSeq Platform
• Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD)
• MicroRNA-223 Regulates Septin-2 and Septin-6 in Stored Platelets
• Acknowledgements to Reviewers

 

For details on the articles, please visit this link ::  https://bit.ly/2IldlyM

CALL FOR PAPERS – Special Thematic Issues

Forthcoming Special Issues of the journal “Current Chemical Biology”

 

“BIOMARKERS AND BIOPROTECTORS EFFECTIVENESS AGAINST ENVIRONMENTAL STRESS AGENTS”

 

Guest Editor(s): Emanuele Calabrò

Tentative Publication Date: April, 2019

For more details please visit: https://bit.ly/2xjlr6y

Email here to submit your paper:  faizan@benthamscience.net

CALL FOR PAPERS – Thematic Issue

Forthcoming Special Issue of the Journal: Current Chemical Biology

 

“BIOMARKERS AND BIOPROTECTORS EFFECTIVENESS AGAINST ENVIRONMENTAL STRESS AGENTS”

 

Guest Editor: Emanuele Calabrò

https://benthamscience.com/journals/current-chemical-biology/#top

 

Hepatitis day related Articles

The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection

 

Journal Name: Current Drug Targets

Author(s): Chang Ho Lee*, Ji Hyun Kim, Seong-Wook Lee*.

 

 

Graphical Abstract:

 

Abstract:

Hepatitis C virus (HCV) is a worldwide major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Accumulating evidence indicates that a number of microRNAs (miRNAs), which are able to exert an effect on liver biology and pathology, can regulate or be regulated by HCV infection. Many studies demonstrate that HCV utilizes host miRNAs and modulates expression of miRNAs in infected hepatocytes for its infection and propagation. In turn, host miRNAs can directly regulate HCV replication through interaction with the HCV RNA genome or by indirectly controlling the host pathways associated with the virus replication, which eventually induce HCV-related liver diseases such as liver fibrosis, hepatic cirrhosis, or HCC. Recently, extracellular miRNAs (circulating miRNAs) detected in human serum and plasma are proposed as biomarker candidates for pathological conditions due to their remarkably stable nature and the non-invasiveness of their detection. Since these circulating miRNAs exhibit consistent levels between healthy individuals but significantly changed profiles in disease conditions, considerable effort has been employed to investigate the alteration in the circulating miRNA pattern that is related with HCV infection and associated liver diseases. In this review, we summarize the features of miRNAs critical for HCVassociated liver disease initiation and progress, and discuss growing evidence that distinctive circulating miRNA patterns are related with HCV infection and associated liver diseases. These will shed light on the development of miRNA-based therapeutic modalities and non-invasive biomarkers for the diagnosis and prognosis of HCV infection and associated diseases.

 

 

For more details, Please visit: http://www.eurekaselect.com/140895

MOST ACCESSED ARTICLE – The Use of Biomarkers in Sepsis – Current Pharmaceutical Biotechnology

Journal: Current Pharmaceutical Biotechnology

Author(s): Konstantinos Giannakopoulos*, Ursula Hoffmann, Uzair Ansari, Thomas Bertsch, Martin Borggrefe,Ibrahim Akin, Michael Behnes

Graphical Abstract:

 

Abstract:

Background: Despite the extended laboratory and clinical study of sepsis, its diagnosis remains a clinical challenge. The initiation of sepsis activates many different biochemical and immunological pathways being expressed by alterations of various molecules in human tissues. The detection and measurement of the concentration of such molecules, known as biomarkers, may be a diagnostic tool of great significance for clinicians dealing with suspected sepsis. Additionally, biomarkers may predict patients ´ outcome and may play a role in monitoring response to therapy.

Methods: Most relevant clinical and experimental biomarker studies on sepsis were retrieved and reviewed in this article.

Results: Although many biomarkers were evaluated for the diagnosis and prognosis in sepsis, until now not one has been proven to be absolutely reliable in the clinical field. Currently C-reactive proteine (CPR) and procalcitonin (PCT) are used worldwide routinely, nevertheless their values may elevate in clinical settings without sepsis, while they often fail to provide reliable prediction of the patient outcome.

Conclusion: This review outlines most relevant circulating biomarkers in sepsis.

To access the article, please visit: http://www.eurekaselect.com/152828